Clinical Trials

2,900 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05615818 2026-05-19

SAFIR-ABC10

Phase 3 Recruiting

800 enrolled

Biliary Tract Neoplasms

NCT05372614 2026-05-18

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Phase 1 Suspended

33 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06126276 2026-05-13

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Phase 1 Active not recruiting

70 enrolled

Other solid neoplasm

Malignant Female Reproductive System Neoplasm

NCT04502602 2026-05-11

iNNOVATE

18 enrolled

Gynecologic

Ovarian Neoplasms

NCT01042379 2026-05-06

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04374305 2026-05-06

INTUITT-NF2

109 enrolled

CNS

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT03919292 2026-04-21

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Phase 1/2 Recruiting

83 enrolled

Phase 1/2 Active not recruiting

Colonic Neoplasms, Pancreatic Neoplasms, Disease Progression

NCT03377387 2026-04-16

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

34 enrolled

Breast Neoplasms

NCT04886531 2026-04-08

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

30 enrolled

Breast Neoplasms

NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Terminated

34 enrolled 15 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT06109467 2026-02-09

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

36 enrolled

Stomach Neoplasms

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2 Completed

140 enrolled 32 charts

Breast Neoplasms

NCT03289039 2026-01-22

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Phase 2 Terminated

21 enrolled 15 charts

Breast Neoplasms

NCT05933395 2026-01-20

GERTRUDE

Phase 1 Active not recruiting

135 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

93 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04965064 2025-12-15

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Phase 1/2 Active not recruiting

22 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT02932280 2025-12-05

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

14 enrolled

CNSLymphoidOther hematologic neoplasm

Disease, Leukemia, Lymphoma, Recurrence, Central Nervous System Neoplasms

NCT02977780 2025-11-10

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Phase EARLY_PHASE1 Recruiting

460 enrolled

CNS

Glioblastoma

NCT06008275 2025-11-10

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05274048 2025-10-29

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Phase 1 Recruiting

18 enrolled

Gastrointestinal Neoplasms, Stomach Neoplasms

NCT05760612 2025-09-25

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Phase 3 Recruiting

300 enrolled

Breast Neoplasms

NCT05919108 2025-09-09

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Phase 2 Not yet recruiting

30 enrolled

Carcinoma, Lobular

NCT07152782 2025-09-03

THUNDER

202 enrolled

Breast Cancer With Brain Metastasis

NCT03094052 2025-06-26

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

Phase 2 Completed

11 enrolled 12 charts

Breast Neoplasms

NCT05243641 2025-06-11

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

Phase 1/2 Terminated

10 enrolled 11 charts